Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 82 entries
View as:

Three Times Daily Dosing of UT-15C

Phase: N/A Priority: Normal
NCT ID: NCT01746485 Org: User:
Start: 07/31/12 End: 07/31/12 Due: 07/31/13

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02882126 Org: User:
Start: 06/30/17 End: 06/30/21 Due: 06/30/22

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00058929 Org: User:
Start: 10/31/02 End: 08/31/05 Due: 08/31/06

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Phase: N/A Priority: Normal
NCT ID: NCT03794583 Org: User:
Start: 12/21/18 End: 11/29/22 Due: 11/29/23

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT03496623 Org: User:
Start: 05/08/18 End: 10/13/22 Due: 10/13/23

Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT05255991 Org: User:
Start: 10/04/22 End: 07/31/25 Due: 07/31/26

A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

Phase: N/A Priority: Normal
NCT ID: NCT04084678 Org: User:
Start: 01/20/21 End: 04/12/23 Due: 04/12/24

Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin

Phase: N/A Priority: Normal
NCT ID: NCT05060315 Org: User:
Start: 07/05/23 End: 12/31/24 Due: 12/31/25

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01172496 Org: User:
Start: 08/31/10 End: - Due: -

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Phase: N/A Priority: Normal
NCT ID: NCT00963027 Org: User:
Start: 09/30/09 End: 10/31/09 Due: 10/31/10

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02603068 Org: User:
Start: 02/29/16 End: 07/31/18 Due: 07/31/19

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Phase: N/A Priority: Normal
NCT ID: NCT00373360 Org: User:
Start: 09/30/06 End: 01/31/08 Due: 01/31/09

Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

Phase: N/A Priority: Normal
NCT ID: NCT01799473 Org: User:
Start: 01/31/13 End: 12/31/14 Due: 12/31/15

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01884038 Org: User:
Start: 06/30/08 End: 06/30/10 Due: 06/30/11

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

Phase: N/A Priority: Normal
NCT ID: NCT00067041 Org: User:
Start: 03/31/03 End: 12/31/03 Due: 12/31/04

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02693171 Org: User:
Start: 03/15/16 End: 12/19/16 Due: 12/19/17

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Phase: N/A Priority: Normal
NCT ID: NCT05943535 Org: User:
Start: 10/30/23 End: 11/30/27 Due: 11/30/28

Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

Phase: N/A Priority: Normal
NCT ID: NCT02847260 Org: User:
Start: 04/30/12 End: 03/31/14 Due: 03/31/15

12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.

Phase: N/A Priority: Normal
NCT ID: NCT00069511 Org: User:
Start: 07/31/03 End: 12/31/04 Due: 12/31/05

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Phase: N/A Priority: Normal
NCT ID: NCT03626688 Org: User:
Start: 08/30/18 End: 12/31/25 Due: 12/31/26

Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT04905693 Org: User:
Start: 09/06/22 End: 06/30/26 Due: 06/30/27

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT04708782 Org: User:
Start: 06/01/21 End: 06/30/25 Due: 06/30/26

Open-Label Study of Oral Treprostinil in Digital Ulcers

Phase: N/A Priority: Normal
NCT ID: NCT00848107 Org: User:
Start: 09/30/09 End: 09/30/11 Due: 09/30/12

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT03055221 Org: User:
Start: 06/10/05 End: 02/25/14 Due: 02/25/15

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02999906 Org: User:
Start: 10/31/17 End: 06/30/22 Due: 06/30/23